XML 21 R10.htm IDEA: XBRL DOCUMENT
v3.24.3

OTHER (INCOME)/EXPENSE, NET | 9 Months Ended
--- | ---
Sep. 30, 2024
Other Nonoperating Income (Expense) [Abstract] |
OTHER (INCOME)/EXPENSE, NET | OTHER (INCOME)/EXPENSE, NET
| Three Months Ended September 30, |  | Nine Months Ended September 30,
Dollars in millions | 2024 |  | 2023 |  | 2024 |  | 2023
Interest expense (Note 10) | $ | 505 |  |  | $ | 280 |  |  | $ | 1,451 |  |  | $ | 850 |
Royalty and licensing income (Note 4) | (180) |  |  | (365) |  |  | (532) |  |  | (1,068) |
Royalty income - divestiture (Note 4) | (284) |  |  | (217) |  |  | (820) |  |  | (623) |
Investment income | (94) |  |  | (107) |  |  | (364) |  |  | (304) |
Litigation and other settlements (a) | — |  |  | (61) |  |  | 71 |  |  | (393) |
Provision for restructuring (Note 6) | 78 |  |  | 141 |  |  | 558 |  |  | 321 |
Integration expenses (Note 6) | 69 |  |  | 54 |  |  | 214 |  |  | 180 |
Equity investment (gains)/losses (Note 9) | (12) |  |  | — |  |  | (221) |  |  | 213 |
Acquisition expense (Note 4) | — |  |  | — |  |  | 50 |  |  | — |
Intangible asset impairment | 47 |  |  | 29 |  |  | 47 |  |  | 29 |
Other(b) | 105 |  |  | (12) |  |  | 134 |  |  | 8 |
Other (income)/expense, net | $ | 234 |  |  | $ | (258) |  |  | $ | 588 |  |  | $ | (787) |
(a) Includes $90 million of income related to the Eisai collaboration termination incurred during the nine months ended September 30, 2024 and $400 million of income related to Nimbus' TYK2 program change of control provision incurred during the nine months ended September 30, 2023. (b) Includes pension settlement charges of $100 million during the three months ended September 30, 2024 and $119 million during the nine months ended September 30, 2024 incurred in connection with the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income pension plan. Litigation and Other Settlements BeiGene Settlement In August 2023, BMS and BeiGene, Ltd. ("BeiGene") entered into an agreement that terminated all contractual relationships and settled all on-going disputes and claims between the parties, including those related to the Abraxane license and supply agreements and related arbitration proceedings that were previously disclosed. As part of this agreement, BMS agreed to transfer 23.3 million of BeiGene ordinary shares of common stock held under a share subscription agreement back to BeiGene resulting in $322 million of expense that was included in Other (income)/expense, net during the three and nine months ended September 30, 2023. The expense was determined based on the closing price of the shares on the date of the transfer. AstraZeneca Settlement In July 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations. AstraZeneca is to pay an aggregate of $560 million to BMS in four payments through September 2026, which would be subject to sharing arrangements with Ono and Dana-Farber. BMS's share is approximately $418 million, of which the net present value of $384 million was reflected in Other (income)/expense during the three and nine months ended September 30, 2023.

X
- Definition The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/720/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 610 -Publisher FASB -URI https://asc.fasb.org/610/tableOfContent + Details
Name: | us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OtherNonoperatingIncomeExpenseAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration